Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPB-111077 in Relapsed or Refractory Acute Myeloid Leukaemia
NCT03197714Phase 1Completed
- Sponsor
- Hospital Universitario 12 de Octubre
- Start
- Sep 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OPB-111077 in acute myeloid leukemia (AML), sponsored by Hospital Universitario 12 de Octubre. Primary endpoint: Dose-limiting toxicity at 28 days. Started Sep 2017; status: completed.
02
Drugs
OPB-111077
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03197714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197714.